Rhythm Pharmaceuticals, Inc. (RYTM)
111.44
+1.44
(+1.31%)
USD |
NASDAQ |
Aug 24, 16:00
111.41
-0.03
(-0.03%)
After-Hours: 20:00
Rhythm Pharmaceuticals EPS Diluted (Quarterly) : -0.7342 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.7342 |
| March 31, 2026 | -0.8348 |
| December 31, 2025 | -0.7302 |
| September 30, 2025 | -0.8192 |
| June 30, 2025 | -0.7534 |
| March 31, 2025 | -0.8059 |
| December 31, 2024 | -0.7246 |
| September 30, 2024 | -0.7346 |
| June 30, 2024 | -0.5501 |
| March 31, 2024 | -2.351 |
| December 31, 2023 | -0.7029 |
| September 30, 2023 | -0.7631 |
| June 30, 2023 | -0.8213 |
| March 31, 2023 | -0.9201 |
| December 31, 2022 | -0.7548 |
| September 30, 2022 | -0.795 |
| June 30, 2022 | -0.8929 |
| March 31, 2022 | -1.048 |
| December 31, 2021 | -0.8527 |
| September 30, 2021 | -0.6987 |
| June 30, 2021 | -0.7048 |
| March 31, 2021 | 0.902 |
| December 31, 2020 | -0.7892 |
| September 30, 2020 | -0.7661 |
| June 30, 2020 | -0.7056 |
| Date | Value |
|---|---|
| March 31, 2020 | -0.7756 |
| December 31, 2019 | -0.7807 |
| September 30, 2019 | -1.042 |
| June 30, 2019 | -1.242 |
| March 31, 2019 | -0.8418 |
| December 31, 2018 | -0.7415 |
| September 30, 2018 | -0.5163 |
| June 30, 2018 | -0.5154 |
| March 31, 2018 | -0.6032 |
| December 31, 2017 | -0.41 |
| September 30, 2017 | -1.78 |
| June 30, 2017 | -0.7854 |
| March 31, 2017 | -0.2774 |
| September 30, 2016 | -0.2636 |
| June 30, 2016 | -0.2406 |
| March 31, 2016 | -0.2279 |
| December 31, 2015 | -0.2489 |
| September 30, 2015 | -0.1267 |
| December 31, 2014 | -0.0281 |
| September 30, 2014 | -0.0091 |
| June 30, 2014 | -0.032 |
| March 31, 2014 | -0.0325 |
| June 30, 2013 | -0.0492 |
| March 31, 2013 | -0.0365 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 0.1822 |
| Aprea Therapeutics, Inc. | -0.0671 |
| Alnylam Pharmaceuticals, Inc. | 1.207 |
| Anika Therapeutics, Inc. | 0.2412 |
| Savara, Inc. | -0.1587 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -49.30M |
| Revenue (Quarterly) | 71.26M |
| Total Expenses (Quarterly) | 120.55M |
| Enterprise Value | 7.562B |
| Gross Profit Margin (Quarterly) | 87.39% |
| Profit Margin (Quarterly) | -69.19% |
| Earnings Yield | -2.80% |
| Normalized Earnings Yield | -2.788 |